Abstract
Inhibitors of HMG-CoA reductase (statins) are widely used for the treatment of hypercholesterolemia. Besides this very important action, several other effects of statins, contributing to the general benefit of patients with coronary heart disease, have recently been demonstrated. These include: stabilization of atheroma plaques; inhibition of platelet aggregation; anti-inflammatory effects; improvement of vasomotor and endothelial function; antiproliferative effects on vascular smooth muscle cells; and effects on fibrinolytic activity, resulting in a decreased mortality from coronary heart disease, regardless of the influence on the serum cholesterol levels. Other effects of statins involve antioxidative, immunomodulatory and potential anti-tumor activities, as has been suggested by a number of studies either demonstrating the beneficiary activities of statins on the rejection of transplanted organs, or the low prevalence of cancer in patients having received statin medication. The aim of the present survey is to summarize current knowledge in this biomedical field and to demonstrate the enormous curative potential of this group of drugs.
Keywords: Statins, HMG-CoA reductase, atherosclerosis, cancer, inflammation, apoptosis, proliferation, immunomodulation
Current Enzyme Inhibition
Title: Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors
Volume: 2 Issue: 3
Author(s): Libor Vítek and Martin Lenicek
Affiliation:
Keywords: Statins, HMG-CoA reductase, atherosclerosis, cancer, inflammation, apoptosis, proliferation, immunomodulation
Abstract: Inhibitors of HMG-CoA reductase (statins) are widely used for the treatment of hypercholesterolemia. Besides this very important action, several other effects of statins, contributing to the general benefit of patients with coronary heart disease, have recently been demonstrated. These include: stabilization of atheroma plaques; inhibition of platelet aggregation; anti-inflammatory effects; improvement of vasomotor and endothelial function; antiproliferative effects on vascular smooth muscle cells; and effects on fibrinolytic activity, resulting in a decreased mortality from coronary heart disease, regardless of the influence on the serum cholesterol levels. Other effects of statins involve antioxidative, immunomodulatory and potential anti-tumor activities, as has been suggested by a number of studies either demonstrating the beneficiary activities of statins on the rejection of transplanted organs, or the low prevalence of cancer in patients having received statin medication. The aim of the present survey is to summarize current knowledge in this biomedical field and to demonstrate the enormous curative potential of this group of drugs.
Export Options
About this article
Cite this article as:
Vítek Libor and Lenicek Martin, Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors, Current Enzyme Inhibition 2006; 2 (3) . https://dx.doi.org/10.2174/157340806777934775
DOI https://dx.doi.org/10.2174/157340806777934775 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Variation of Antioxidant Capacity in Different Layers of Onion (Allium cepa L.) At Two Different Stages of Maturation
Current Nutrition & Food Science Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design New Applications of Oleanolic Acid and its Derivatives as Cardioprotective Agents: A Review of their Therapeutic Perspectives
Current Pharmaceutical Design Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail?
Recent Patents on Inflammation & Allergy Drug Discovery Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Recombinant Activated Factor VII as a General Haemostatic Agent:Evidence-Based Efficacy and Safety
Current Drug Safety Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration
Current Reviews in Clinical and Experimental Pharmacology Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies
Vascular Disease Prevention (Discontinued)